These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31771627)

  • 1. BRCA1 mutation influences progesterone response in human benign mammary organoids.
    Davaadelger B; Choi MR; Singhal H; Clare SE; Khan SA; Kim JJ
    Breast Cancer Res; 2019 Nov; 21(1):124. PubMed ID: 31771627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
    Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
    Lee O; Bosland MC; Wang M; Shidfar A; Hosseini O; Xuei X; Patel P; Schipma MJ; Helenowski I; Kim JJ; Clare SE; Khan SA
    Cancer Lett; 2021 Nov; 520():255-266. PubMed ID: 34329741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
    Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
    Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone receptor A stability is mediated by glycogen synthase kinase-3β in the Brca1-deficient mammary gland.
    Wang S; Li Y; Hsu PH; Lee SY; Kim Y; Lee EYP
    J Biol Chem; 2013 Sep; 288(36):26265-26274. PubMed ID: 23880761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
    Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
    Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.
    Hilton HN; Patterson McDonald LJ; Santucci N; van der Bent FR; Silvestri A; Graham JD; Clarke CL
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):257-270. PubMed ID: 31104199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Szabova L; Gordon MB; Lu L; Pate N; Bassel L; Iacovelli AJ; Karim B; Homan PJ; Householder DB; Guerin TM; Burkett S; Day AM; Custer W; Weaver Ohler Z
    Breast Cancer Res; 2022 Nov; 24(1):75. PubMed ID: 36333737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
    Vilasco M; Communal L; Hugon-Rodin J; Penault-Llorca F; Mourra N; Wu Z; Forgez P; Gompel A;
    Breast Cancer Res Treat; 2013 Nov; 142(2):283-96. PubMed ID: 24166279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.
    Calvo V; Beato M
    Cancer Res; 2011 May; 71(9):3422-31. PubMed ID: 21531767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of
    Sau A; Cabrita MA; Pratt MAC
    Cancer Prev Res (Phila); 2018 Feb; 11(2):69-80. PubMed ID: 29101208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Kotsopoulos J; Singer C; Narod SA
    Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
    Lee EY
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):68-73. PubMed ID: 18197009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
    Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
    Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
    Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
    Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.